Abelson Taylor’s strongest offering and best competitive advantage will
continue to be brand strategy, positioning, message development, and
compelling creative. As channels will continue to evolve and media will
change, what will remain constant is that the partner who does the best job
of creating, discovering, and communicating the compelling content that
moves these important brands will be the agency that thrives.
Aczone Gel is a prescription topical medicine used to treat acne in people
ages 12 and older. The Aczone commercial was created for Allergan
ABELSONTAYLOR – ACZONE
A thriving, engaging culture, combined with great work and top talent,
make Dudnyk the place to be in 2014, agency leaders say. “Our agency
culture fosters creativity, strong teams, and personal growth,” says President
Frank X. Powers. “This allows us to do what we do best – unleash the
inciteful healthcare marketing process to hone strategy that leads to
transformative branding and creative for our clients.”
Aiming for “The Greatest Pharma Launch of All Time,” the Sovaldi brand
team developed the “Advancing What’s Possible” campaign, which has
helped drive the brand to sales projections of more than $5 billion in 2014,
its first full year on the market.
CAHG – SOVALDI
In the treatment of HCV
CINRYZE® (C1 esterase inhibitor [human]) is indicated
for routine prophylaxis against angioedema attacks in
adolescent and adult patients with Hereditary
Important Safety Information
CINRYZE is contraindicated in patients who have
manifested life-threatening immediate hypersensitivity
reactions, including anaphylaxis to the product.
Severe hypersensitivity reactions may occur. Consider
treatmentmethods carefully, because hypersensitivity
reactions and HAE attacks may have similar symptoms.
In the case of hypersensitivity, discontinue CINRYZE
and institute appropriate treatment. Have epinephrine
immediately available for treatmentof an acute severe
Postmarketing adverse reactions include local infusion site
reactions (including pain, rash, erythema, inflammation or
hematoma at the infusion site). Postmarketing thrombotic
events have been reported, including catheter-related and
deep venous thromboses, transient ischemic attack, and stroke.
Before prescribing CINRYZE, please read
the Brief Summary on the adjacent page.
Thrombotic events have been reported in patients
receiving CINRYZE for routine prophylaxis. Thrombotic
events also have been reported in patients receiving
off-label high dose C1 esterase inhibitor therapy.
Monitor closely patients with known risk factors for
Because CINRYZE is made from human blood, it
may carry a risk of transmitting infectious agents e.g.
viruses and, theoretically, the Creutzfeldt-Jakob disease
(CJD) agent. ALL infections possibly transmitted by
CINRYZE should be reported by a physician orother
healthcare provider to ViroPharma Medical Information
(866) 331-5637. All risks and benefits should be
discussed with the patient before prescribing or
administering this product.
The only serious adverse reaction observed in clinical
studies of CINRYZE was cerebrovascularaccident.
The most common adverse reactions observed were
headache, nausea, rash, and vomiting.
The swelling of HAE impacts each patient
differently, so disease severity cannot be
determined by attack frequency alone. 12
CINRYZE® (C1 esterase inhibitor [human])
isthe only FDA-approved C1 esterase inhibitor
for routine prophylaxis against HAE attacks
in adolescents and adults. Helpyour patients
move forward. Learn more about replacement
therapy with CINRYZE at www.cinryze.com.
CINRYZE, EMPOWERING PREVENTION, and the assocated ogo are ether regstered
trademarks or trademarks of VroPharma Boogcs, Inc. VIROPHARMA and the assocated
ogo are trademarks of VroPharma Incorporated.
© 2013 VroPharma Incorporated. A rghts reserved. DD1336 07/2013
Put the Power of
Prevention in Her Hands
In the management of hereditary angioedema (HAE)
References: 1. Zura w B, Red M,Lumry W, et a.US HAE Assocaton Consensus Document: an
approach to the dagnoss and treatment of HAE. Gudenes from the US HAEA Medca Advsory
2. Bowen T, Ccard M, Farkas H, et a. 2010 Internatona consensus agorthm
for the dagnoss, therapy and management of heredtary angoedema. Aergy Asthma Cnca
Immuno. 2010;61: 24.
Not an actua HAE patent.
When hypersensitivity to E. coli asparaginase
disrupts his treatment course…
T he story of his journey may
continue with Erwinaze
Continue the Journey
Today, she presents
with dry eye symptoms.
What will she look like by
the time she is diagnosed?
For millions of dry eye patients,
their symptoms could be an early sign
of a progressive autoimmune disease.1, 2
As many as 1 in 10 patients with dry eye also have Sjögren’s
Syndrome, a chronic condition of deteriorating exocrine
glands that can have significant systemic ramifications. 2-4
Today, it takes an average of 4.7 years to receive an
accurate diagnosis. 2 Together with the Sjögren’s
Syndrome Foundation, Nicox is out to change that.
Join us in the fight at
1.855.MY.NICOX (1.855.696.4269) to learn more.
Uncover a potential systemic cause
of dry eye before it takes hold